局部进展期胃癌新辅助化疗后腹腔镜胃切除术短期结局的前瞻性单臂临床试验
这项前瞻性单臂临床试验纳入80例新辅助化疗后行腹腔镜胃切除术的患者,并通过1:2倾向性评分匹配建立160例未行新辅助化疗的同期历史对照组。结果显示新辅助化疗组术中出血更少、恢复更快,术后并发症与严重并发症无显著差异,且ypT4期、ypN3期比例及转移淋巴结数更低。
要点
- 新辅助化疗组主要病理退缩率27.5%,客观影像学缓解率64.0%。
核心结论
- 腹腔镜胃切除术可通过新辅助化疗肿瘤降期获得改善的短期结局,且不增加术后并发症发生率。
- 仍需进一步多中心前瞻性临床试验验证。
研究设计与样本
- 前瞻性单臂临床试验,纳入80例新辅助化疗后行腹腔镜胃切除术的患者。
- 通过1:2倾向性评分匹配建立含160例未行新辅助化疗的同期历史对照组的腹腔镜胃切除术患者。
主要发现
- 新辅助化疗组主要病理退缩率为27.5%,客观影像学缓解率(完全缓解+部分缓解)为64.0%。
临床怎么用
- 对于局部进展期胃癌,新辅助化疗后行腹腔镜胃切除术可获得肿瘤降期并改善短期结局,且不增加术后并发症。
- 新辅助化疗后出现客观缓解的患者短期手术结局更优。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Laparoscopic surgical approaches for gastric cancer after neoadjuvant chemotherapy are increasing, yet there is limited evidence of their safety and effectiveness. METHODS: This prospective single-armed clinical trial enrolled 80 neoadjuvant chemotherapy patients who underwent laparoscopic gastrectomy. In addition, to better analyze the outcomes of this study, 1:2 propensity score matching was performed, and a contemporaneous historic control group containing 160 laparoscopic gastrectomy patients without neoadjuvant chemotherapy was established. RESULTS: Analyses were performed to compare the neoadjuvant chemotherapy group (n = 80) and the control group (n = 160). The general clinical data of both groups were comparable. The neoadjuvant chemotherapy group showed less intraoperative bleeding (P = .029) and recovered more quickly than the control group (all P < .05). The 2 groups did not exhibit major differences in terms of postoperative complications (P = .679) or severe complications (P = .055). The proportion of patients with ypT4 stage and ypN3 stage disease in the neoadjuvant chemotherapy group totaled 20.7% and 23.8%, respectively, which was significantly lower than that observed in the control group (P < .05). The number of metastatic lymph nodes was 4.8 ± 7.0 in the neoadjuvant chemotherapy group, which was lower than that in the control group (P < .001). In the neoadjuvant chemotherapy group, the major pathological regression rate was 27.5%, while the objective radiologic response rate (complete response + partial response) was 64.0%. In contrast to nonresponding patients, the patients who experienced an objective response had a shorter operation time (P < .001), less intraoperative bleeding (P < .001), and fewer metastatic lymph nodes (P = .005). The short-term effects observed in the nonresponding patients were similar to those observed in the control group. CONCLUSION: Laparoscopic gastrectomy could achieve improved short-term outcomes through NACT tumor downstaging without increasing the incidence of postoperative complications. Further multicenter and prospective clinical trials are warranted.
引用
- Tu RH, Lin JX, Xie JW, et al. Assessment of the short-term outcomes of laparoscopic gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: A prospective single-armed clinical trial. Surgery. 2022. PMID: 35246330. doi:10.1016/j.surg.2022.01.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。